InterCure Ltd. (NASDAQ:INCR - Get Free Report) saw a large increase in short interest in March. As of March 31st, there was short interest totalling 34,100 shares, an increase of 24.5% from the March 15th total of 27,400 shares. Based on an average daily trading volume, of 20,800 shares, the short-interest ratio is presently 1.6 days. Approximately 0.1% of the shares of the stock are short sold.
InterCure Price Performance
INCR traded up $0.09 during midday trading on Friday, hitting $1.46. The stock had a trading volume of 730 shares, compared to its average volume of 34,680. InterCure has a 1 year low of $1.17 and a 1 year high of $3.72. The company has a quick ratio of 1.15, a current ratio of 1.78 and a debt-to-equity ratio of 0.15. The business has a fifty day moving average of $1.47 and a 200 day moving average of $1.55.
Institutional Investors Weigh In On InterCure
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in shares of InterCure during the third quarter valued at approximately $43,000. Jane Street Group LLC purchased a new position in shares of InterCure during the third quarter valued at approximately $49,000. Finally, Moore Capital Management LP bought a new position in shares of InterCure during the fourth quarter valued at $156,000. 8.34% of the stock is currently owned by institutional investors.
InterCure Company Profile
(
Get Free Report)
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Recommended Stories
Before you consider InterCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InterCure wasn't on the list.
While InterCure currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
